|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US8114863||GUERBET||Compounds comprising short aminoalcohol chains and metal complexes for medical imaging|| |
(4 years from now)
|US10973934||GUERBET||Gadolinium bearing PCTA-based contrast agents|| |
(15 years from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11590246||GUERBET||Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process|| |
(16 years from now)
Elucirem is owned by Guerbet.
Elucirem contains Gadopiclenol.
Elucirem has a total of 3 drug patents out of which 0 drug patents have expired.
Elucirem was authorised for market use on 21 September, 2022.
Elucirem is available in solution;intravenous dosage forms.
Drug patent challenges can be filed against Elucirem from 2026-09-21.
The generics of Elucirem are possible to be released after 17 January, 2040.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Chemical Entity Exclusivity (NCE)||Sep 21, 2027|
NCE-1 date: 2026-09-21
Market Authorisation Date: 21 September, 2022
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic